Gate2Brain

What Gate2Brain does

Gate2Brain is a Barcelona-based preclinical biotechnology company developing a proprietary peptide-based technology platform to enable therapeutics to cross biological barriers, with a primary focus on the blood-brain barrier (BBB). Founded in July 2020 as a spin-off from IRB Barcelona, the University of Barcelona, and Hospital Sant Joan de Déu Barcelona, the company has built a portfolio of three families of peptide shuttles (anchored by MiniAp4) that conjugate to diverse drug cargoes — including small molecules, peptides, nanoparticles, proteins, and antibodies — and ferry them across the BBB using natural nutrient transport mechanisms without disrupting the barrier's protective function. Preclinical MiniAp4 conjugates have demonstrated up to 100-fold greater brain drug transport versus unmodified candidates, and the lead asset G2B-002 (MiniAp4 conjugated to the topoisomerase I inhibitor SN-38) has shown ~84-88% cell kill in DIPG coculture BBB models and potent activity across multiple rare pediatric cancer indications including DIPG, pediatric high-grade gliomas, Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma. G2B-002 has been granted Orphan Drug Designation by both the FDA and EMA, and the broader platform is protected by a portfolio of 6 patents. First-in-human clinical trials are targeted for FY28.

The company operates a B2B licensing and co-development model, pursuing strategic partnerships with pharmaceutical and biotech companies rather than building internal commercial sales infrastructure. Go-to-market is executed through direct enterprise engagement at partnering conferences (RESI JPM, BioJapan, 4YFN, BioSpain, TIDES USA, World Health Expo Osaka), supplemented by media coverage, LinkedIn/YouTube presence, and pediatric innovation ecosystem participation (i4KIDS, PNOC, EIT Health). Gate2Brain has secured more than €4.5M in cumulative funding prior to its June 2026 €7M strategic equity investment from Shilpa Biocare (Shilpa Medicare subsidiary) for a 30.4% stake, implying a post-money valuation of approximately €23M. Capital sources include the EIC Accelerator (€2.5M grant), a €1M bridge round, Fundación Botín, Banco Sabadell BStartup Health, CDTI, CaixaResearch, ENISA, and the EU Next Generation programme. A Series A round is currently in design with 50% EIC co-investment committed to fund the G2B-002 IND-enabling and clinical transition. The team comprises 1–10 employees led by CEO & CSO Dr. Meritxell Teixidó, with a scientific advisory bench that includes nanotech expert Alejandro Sosnik (Technion).

Name

Gate2Brain

Legal name

GATE2BRAIN, S.L.

Website

https://gate2brain.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Gate2Brain is a Barcelona-based preclinical biotech developing proprietary peptide shuttle technology (MiniAp4) to deliver therapeutics across the blood-brain barrier, with lead candidate G2B-002 in pediatric brain tumors under FDA and EMA Orphan Drug Designation.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Delivery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Blood-brain barrier delivery
• Peptide shuttle therapeutics
• CNS drug delivery
• Pediatric brain tumor therapeutics
• Biopharmaceutical drug delivery

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Co-development Agreements: Gate2Brain pursues licensing agreements and co-development partnerships with pharmaceutical companies for its peptide shuttle technology platform. The platform is positioned as ready for R&D and out-licensing agreements. The company develops proprietary therapeutic candidates (G2B-002) and licenses its technology or partners for further development and commercialization.
2. Strategic Equity Partnerships with Pharmaceutical Companies: Gate2Brain enters strategic equity partnerships where pharmaceutical partners invest capital in exchange for equity stakes, while providing CMC, manufacturing, and regulatory expertise. The June 2026 Shilpa Biocare partnership (€7M for 30.4% equity) exemplifies this model, combining capital infusion with operational partnership.
3. Non-dilutive and Dilutive Funding: Gate2Brain has raised multiple rounds of funding including European Innovation Council Accelerator (€2.5M), a €1M bridge round, and the €7M Shilpa Biocare strategic equity round. The company is currently designing a Series A funding round with 50% co-investment from EIC Accelerator.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Gate2Brain develops a proprietary peptide-based delivery technology platform, comprising three families of peptide shuttles, that enables therapeutics to cross biological barriers such as the blood-brain barrier without compromising their protective function. The platform is applied to multiple drug cargoes (small molecules, peptides, nanoparticles, proteins, antibodies) and supports the company's lead therapeutic candidate G2B-002 for aggressive pediatric brain tumors (DIPG and pediatric glioblastoma). Gate2Brain monetizes the platform through out-licensing, co-development, and strategic equity partnerships with global pharmaceutical companies.

Product overview

Gate2Brain is a biotech company offering a proprietary peptide-based technology platform for delivering therapeutics across biological barriers, particularly the blood-brain barrier. The core product is G2B-002, a lead therapeutic candidate that uses the MiniAp4 peptide shuttle to transport SN-38 for treating pediatric brain tumors (DIPG, pGBM). The technology platform consists of three families of peptide shuttles that can transport various cargo types (small molecules, peptides, nanoparticles, proteins, antibodies) and is applicable to multiple therapeutic areas including brain tumors and other central nervous system diseases. G2B-002 has received Orphan Drug Designation from both FDA and EMA.

Differentiator

Problem solved

Functional benefit

Products and services

• G2B-002 Gate2Brain's lead therapeutic candidate and proof-of-concept for its peptide shuttle platform. G2B-002 pairs the MiniAp4 peptide shuttle with SN-38 (a topoisomerase I inhibitor) to deliver chemotherapy across the blood-brain barrier for aggressive pediatric brain tumors including DIPG (Diffuse Intrinsic Pontine Glioma) and pediatric glioblastoma (pGBM), with demonstrated preclinical activity in DIPG, pediatric high-grade gliomas, Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma. Granted Orphan Drug Designation by both the FDA and EMA.
• Gate2Brain Peptide Shuttle Technology Platform A proprietary technology platform based on three families of peptide shuttles (including MiniAp4) that conjugate to drug cargoes—small molecules, peptides, nanoparticles, proteins, and antibodies—to improve their biopharmaceutical properties in vitro and in vivo and enable them to cross biological barriers such as the blood-brain, blood-retinal, skin, and tumor barriers using natural nutrient transport mechanisms. The platform is positioned for out-licensing and co-development with pharmaceutical and biotech partners.

Quantifiable outcome

• Up to 100-fold greater brain drug transport in preclinical studies with MiniAp4 peptide shuttle technology
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC)coreStrategic or Co-development PartnerLong-standing collaboration with Dr. Macarena Sanchez's team at IPBLN-CSIC in Granada, Spain. Reinforced through a Torres Quevedo Postdoctoral contract from the State Research Agency, resulting in Marina Plaza joining Gate2Brain as Chemist Research Scientist to explore the application of Gate2Brain's shuttle technology for other drug modalities.
• Pacific Pediatric Neuro Oncology Consortium (PNOC)coreStrategic or Co-development PartnerCollaboration with PNOC physicians and scientists specializing in diffuse midline glioma (DMG) as part of the Pediatric Diffuse Midline Glioma International Meeting hosted at SJD Pediatric Cancer Center in Barcelona. Joint research and clinical trials session on DMG.
• Galenus Foundation (Austria)minorStrategic or Co-development PartnerCollaboration with the Galenus Foundation as part of the 12th Galenus International Workshop 'Bioengineering the Future of Drug Delivery' held at i3S – Instituto de Investigação e Inovação em Saúde in Porto, Portugal. Gate2Brain's CEO and Research Scientist participated in the 'Translation-Driven: From Bench to Bedside' session.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Angiochem: Angiochem develops the Angiopep-2 peptide shuttle for transporting therapeutics across the blood-brain barrier — directly analogous to Gate2Brain's MiniAp4 technology in mechanism and end-application (CNS drug delivery via peptide conjugation).
• Vect-Horus: Vect-Horus develops proprietary peptide-based vectors (VECTrans) that ferry drugs across the blood-brain barrier — a near-identical platform play to Gate2Brain's MiniAp4, focused on out-licensing the BBB-shuttle technology to pharma partners.
• Bioasis Technologies: Bioasis develops the xB3 platform — a peptide-based BBB delivery technology for oncology and rare CNS indications — making it a close functional peer to Gate2Brain at a similar preclinical-to-early-clinical stage.

Broad incumbents

• Denali Therapeutics: Denali's enzyme transport vehicle (ETV) platform is a leading BBB-delivery technology used to transport biologics including antibodies and enzymes into the brain — overlapping with Gate2Brain's peptide-shuttle approach but at significantly larger scale and clinical maturity.
• Voyager Therapeutics: Voyager develops gene therapies and AAV-based delivery platforms targeting CNS diseases, including programs aimed at crossing the blood-brain barrier — a broader CNS-delivery peer operating at clinical scale.
• ArmaGen: ArmaGen (acquired by Sobi) developed an antibody-based BBB delivery platform using the human insulin receptor — a leading BBB-crossing technology peer to Gate2Brain's peptide shuttle approach with greater clinical maturity.

Regional players

• JCR Pharmaceuticals: JCR Pharmaceuticals developed the J-Brain Cargo technology for BBB delivery of biologic therapies, analogous to Gate2Brain's MiniAp4. JCR is a Japan-based specialty pharma with established CNS programs using BBB-shuttle technology.

Emerging players

• Kazia Therapeutics: Kazia develops paxalisib for glioblastoma and DIPG specifically, directly overlapping with Gate2Brain's lead pediatric brain tumor indication, though without a proprietary delivery platform.
• Day One Biopharmaceuticals: Day One is a pediatric oncology-focused biotech commercializing therapies for rare childhood cancers including brain tumors — directly comparable to Gate2Brain's pediatric oncology customer segment with greater commercial maturity.
• Midatech Pharma: Midatech develops nano-formulations and polymer-based drug delivery including programs for brain cancer — overlapping with Gate2Brain's G2B-002 self-assembled nanoformulation approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCb6AqvzLipzc2GWfymwlOKw/featured
• LinkedInlinkedin.com/company/gate2brain

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gate2Brain